12/11/2024
7:30 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2024
7:32 AM | NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form 425 | |
12/10/2024
7:30 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K/A | |
12/03/2024
7:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/26/2024
11:15 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form EFFECT | |
11/21/2024
3:01 PM | Hafner Ronald (Filed by)
NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form SC 13G/A | |
11/18/2024
7:30 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
11/15/2024
4:00 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/14/2024
6:27 PM | Lind Global Fund II LP (Filed by)
NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form SC 13G/A | |
11/08/2024
3:00 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/05/2024
3:30 PM | NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form 425 | |
11/05/2024
7:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/04/2024
6:39 PM | NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
YA II PN, Ltd. (Filed by)
| Form SC 13G/A | |
11/04/2024
5:20 PM | Grisard Felix (Filed by)
NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form SC 13G/A | |
11/04/2024
7:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/04/2024
7:02 AM | NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form 425 | |
10/28/2024
7:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/23/2024
3:00 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form F-3
Registration statement for securities of certain foreign private issuers | |
10/22/2024
3:01 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/21/2024
4:19 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
10/18/2024
3:31 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2024
12:24 PM | ALPHA CAPITAL ANSTALT (Filed by)
NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form SC 13G | |
10/15/2024
8:09 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/11/2024
7:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/11/2024
6:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/01/2024
3:01 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/25/2024
7:13 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/19/2024
3:01 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/13/2024
4:01 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/27/2024
3:01 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form F-1
Registration statement for securities of certain foreign private issuers | |
08/26/2024
3:40 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/30/2024
3:30 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2024
8:16 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
07/01/2024
7:26 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 424B5 | |
07/01/2024
7:09 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/27/2024
3:54 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/25/2024
11:15 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form EFFECT | |
06/25/2024
3:31 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/25/2024
8:28 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/28/2024
8:13 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/24/2024
4:25 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
$20k in extra income? (Ad) My friend Alex Reid just might have created my favorite strategy right now.
You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible….
While still showing his traders how to target big money.
This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared.
And that’s just just a quarter of the total trade alerts he’s sent out.
The true total profit potential his beta-testers have had the chance to target is far larger than $20k.  Alex recorded a special video training where he reveals exactly how much. |
05/22/2024
8:10 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/19/2024
4:16 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/08/2024
3:11 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/27/2024
6:37 PM | Lind Global Fund II LP (Filed by)
NLS Pharmaceutics Ltd. (Subject)
NLS Pharmaceutics (Subject)
| Form SC 13G | |
03/22/2024
9:24 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 424B5 | |
03/21/2024
4:14 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2024
11:58 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2024
8:06 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/14/2024
8:00 AM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/29/2023
3:30 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/22/2023
3:02 PM | NLS Pharmaceutics Ltd. (Filer)
NLS Pharmaceutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
